Moderna named Jorge Gomez as CFO in April, and it was revealed that he also quit just two days into his role. The American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, announced this week the immediate departure of its chief financial officer.
It’s unclear if Gomez was fired or resigned as the newly appointed chief financial officer at Moderna. But it was reported that his departure was related to the ongoing internal financial investigation of Dentsply Sirona Inc. Said company was Gomez’s former employer, and it recently disclosed the investigation.
“The Audit Committee is also investigating allegations that certain former and current senior executives directed the company’s use of these incentives and other actions to achieve executive compensation targets in 2021,” New York Post cited Dentsply in a filing.
According to fox business, the probe focuses on the dental equipment and supplies manufacturing company’s use of incentives to sell its dental products to distributors. The survey covers sales for the third and fourth quarters of 2021.
Investigators are checking whether these inducements were properly accounted for and whether these sales were disclosed in periodic reports to the United States Securities and Exchange Commission (SEC). Given that Gomez worked in the finance unit of Dentsply Sirona, it is therefore possible that he is also under investigation; thus, he left Moderna shortly after being named chief financial officer.
“Today announced that its recently appointed Chief Financial Officer, Jorge Gomez, has left the company, effective immediately,” Moderna said in a statement. Press release. “The announcement follows the public disclosure on May 10 by Mr. Gomez’s former employer, Dentsply Sirona Inc., of an ongoing internal investigation into certain matters, including financial reporting.”
Moderna also announced that Davide Meline will continue his work as the company’s chief financial officer following Gomez’s departure. It was reported that Gomez would still receive his 12-month salary, which would be $700,000 in total, and Consolidated Omnibus Budget Reconciliation Act (COBRA) coverage for one year. Again, he will lose his signing bonus and his eligibility for relocation reimbursements.